ER+/HER2- Early or Locally Advanced/Metastatic Breast Cancer
1 clinical trials · Condition
◉ Watch ER+/HER2- Early or Locally Advanced/Metastatic Breast Cancer
| Record | Firm | Date |
|---|---|---|
| Expanded Access Program to Provide Giredestrant to Participants With ER+, HER2- Early or Locally Advanced/Metastatic Breast Cancer (NCT07643831) | Genentech, Inc. |
Track ER+/HER2- Early or Locally Advanced/Metastatic Breast Cancer automatically
Every clearance here is in the API, with alerts when new ones post.